Accessibility Menu

Fresenius SE & Co(FRA) FRE

Market Cap€25.67BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)+6,611%
5 Year+3%
1 Year-3%
1 Month+2%
€45.29
-0.65%
-0.29Today
Fresenius SE & Co last closing stock price
MetricPriceDate
Last closeEUR 45.252026-08-31
Fresenius SE & Co stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.72%EUR 46.042026-08-24
1 month+1.64%EUR 44.522026-07-31
3 month+24.14%EUR 36.452026-06-02
Year to date-7.62%EUR 48.982025-12-30
1 year-2.5%EUR 46.412025-08-29
3 year+53.7%EUR 29.442023-09-01
5 year+2.61%EUR 44.102021-09-01
Since inception+6,610.79%EUR 0.681992-11-13

Fresenius SE & Co Financials at a Glance

Market Cap

€25.67BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€23.41K

Net Income (TTM)

€1.63K

EPS (TTM)

€2.70

P/E Ratio

16.87

Dividend

€1.05

Beta (Volatility)

0.04 (Low)

Price

€45.29

Volume

676

Open

€45.85

Previous Close

€45.29

Daily Range

€45.13 - €45.85

52-Week Range

€35.19 - €52.84

Estimated Earnings Date

N/A

FRE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fresenius SE & Co

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.

Industry

Healthcare Providers and Services

Employees

178,486

CEO

Michael Sen, MBA

FRE Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

8.25%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

5.93%

Dividend Yield

2.30%

Payout Ratio

N/A

Stock Overview

Market Cap

€25.67BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

563.24M

Volume

676

Avg. Volume

1.27K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Fresenius SE & Co Performance Analysis

Fresenius SE & Co annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 21,329,000,000-42.5%
20232023-12-31EUR 21,067,000,000-1.2%
20242024-12-31EUR 21,954,000,0004.2%
20252025-12-31EUR 22,873,000,0004.2%
Fresenius SE & Co annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.44-25.0%
20232023-12-31EUR -1.05N/A
20242024-12-31EUR 0.84N/A
20252025-12-31EUR 2.24168.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€5.95K

+1.1%

Gross Profit

€1.55K

+1.1%

Gross Margin

26.07%

+1.0%

Market Cap

€25.67BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€0.12

+0.9%

Employees

178,486

+1.0%

Net Income

€399.00

+1.2%

EBITDA

€882.00

+1.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€12.70K

-9.8%

Total Debt

€11.42K

+0.9%

Accounts Receivable

€4.36K

+1.1%

Inventory

€2.77K

+1.1%

Long Term Debt

€9.55K

+0.9%

Short Term Debt

€1.86K

+0.8%

Return on Assets

3.77%

+1.2%

Return on Invested Capital

4.04%

+1.1%

Free Cash Flow

€204.00

+0.8%

Operating Cash Flow

€458.00

+0.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About FRE

What is the current price of Fresenius SE & Co?

Fresenius SE & Co is trading at €45.29 per share.

What is the 52-week range for Fresenius SE & Co?

Over the past 52 weeks, Fresenius SE & Co has traded between €35.19 and €52.84.

How much debt does Fresenius SE & Co have?

As of the most recent reporting period, Fresenius SE & Co reported total debt of €11.42B.

How much cash does Fresenius SE & Co have on hand?

Fresenius SE & Co reported €1.28B in cash and cash equivalents in its most recent financial results.

What is Fresenius SE & Co’s dividend yield?

Fresenius SE & Co currently has a dividend yield of 2.30%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.